niacin has been researched along with Insulin Resistance in 61 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG)." | 9.22 | Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. ( Jiang, XS; Liu, L; Ning, N; Tan, MH; Wei, P; Xiao, WY; Yi, D; Zhou, L, 2016) |
| "This study examined whether the increase of adiponectin associated with extended-release (ER) niacin/laropiprant combination attenuates the adverse effect of niacin on glucose and insulin resistance in Hong Kong Chinese patients with dyslipidaemia." | 9.20 | Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia. ( Hu, M; Masuda, D; Tomlinson, B; Yamashita, S; Yang, YL, 2015) |
| " The goal of this study was to determine the effect of niacin administration on serum total- and phosphorylated fetuin-A (phosphofetuin-A) concentrations in individuals with MetS and correlate with changes in serum lipids, insulin sensitivity, and markers of inflammation." | 9.14 | Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. ( Grandjean, PW; Huang, EY; Kaushik, SV; Kim, T; Mahurin, AJ; Mathews, ST; Plaisance, EP, 2009) |
| "We report the case of a 63-year-old obese man with a rapid-onset of widespread acanthosis nigricans (AN) in the setting of having recently initiated treatment with niacin for dyslipidemia." | 8.87 | Acanthosis nigricans in the setting of niacin therapy. ( Defelice, T; Hartman, R; Meehan, S; Sanchez, M; Tzu, J, 2011) |
| "To investigate nicotinamide's action on glucose metabolism, and the association between niacin consumption and obesity prevalence." | 7.76 | Chronic niacin overload may be involved in the increased prevalence of obesity in US children. ( Bian, FN; Guo, M; Li, D; Liu, QG; Luo, N; Sun, WP; Zhao, ZG; Zhou, SS; Zhou, YM, 2010) |
| "Niacin was found to increase secretion of lymph HDL and miR-223 by at least 50-60% and to deplete the TGs associated with HDL compared with the nontreated IR group." | 5.48 | Intestinal lymphatic HDL miR-223 and ApoA-I are reduced during insulin resistance and restored with niacin. ( Borthwick, F; Haase, T; Jacome, M; Kontush, A; Mangat, R; Nelson, R; Proctor, SD; Vine, DF, 2018) |
| "The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG)." | 5.22 | Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. ( Jiang, XS; Liu, L; Ning, N; Tan, MH; Wei, P; Xiao, WY; Yi, D; Zhou, L, 2016) |
| "This study examined whether the increase of adiponectin associated with extended-release (ER) niacin/laropiprant combination attenuates the adverse effect of niacin on glucose and insulin resistance in Hong Kong Chinese patients with dyslipidaemia." | 5.20 | Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia. ( Hu, M; Masuda, D; Tomlinson, B; Yamashita, S; Yang, YL, 2015) |
| " The goal of this study was to determine the effect of niacin administration on serum total- and phosphorylated fetuin-A (phosphofetuin-A) concentrations in individuals with MetS and correlate with changes in serum lipids, insulin sensitivity, and markers of inflammation." | 5.14 | Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. ( Grandjean, PW; Huang, EY; Kaushik, SV; Kim, T; Mahurin, AJ; Mathews, ST; Plaisance, EP, 2009) |
| "Recently we have demonstrated that treatment with niacin raises adiponectin between 52% and 95% in patients with the metabolic syndrome." | 5.13 | Preferential increase in high-molecular weight adiponectin after niacin. ( Luley, C; Westphal, S, 2008) |
| "We report the case of a 63-year-old obese man with a rapid-onset of widespread acanthosis nigricans (AN) in the setting of having recently initiated treatment with niacin for dyslipidemia." | 4.87 | Acanthosis nigricans in the setting of niacin therapy. ( Defelice, T; Hartman, R; Meehan, S; Sanchez, M; Tzu, J, 2011) |
| "Ecological evidence suggests that niacin (nicotinamide and nicotinic acid) fortification may be involved in the increased prevalence of obesity and type 2 diabetes, both of which are associated with insulin resistance and epigenetic changes." | 3.79 | Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. ( Cao, JM; Cao, Y; Gong, XJ; Guo, J; Guo, M; Li, D; Lun, YZ; Luo, N; Sun, WP; Tian, YJ; Zhou, SS, 2013) |
| "To investigate nicotinamide's action on glucose metabolism, and the association between niacin consumption and obesity prevalence." | 3.76 | Chronic niacin overload may be involved in the increased prevalence of obesity in US children. ( Bian, FN; Guo, M; Li, D; Liu, QG; Luo, N; Sun, WP; Zhao, ZG; Zhou, SS; Zhou, YM, 2010) |
| "ER-niacin's role in the treatment of antiretroviral therapy-associated dyslipidemia requires further evaluation, but the results of this pilot study indicate that it is safe and tolerated and provides a valuable treatment option." | 2.71 | Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. ( Claxton, S; DeMarco, D; Drechsler, H; Gerber, MT; Mondy, KE; Powderly, WG; Stoneman, J; Tebas, P; Yarasheski, KE, 2004) |
| " A range of dosing regimens was analyzed and predictions made for optimizing NiAc delivery to minimize FFA exposure." | 2.55 | Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments. ( Almquist, J; Andersson, R; Chappel, MJ; Evans, ND; Gabrielsson, J; Jirstrand, M; Kroon, T; Oakes, ND, 2017) |
| "Niacin has beneficial effects on plasma lipoproteins and has demonstrated clinical benefits in reducing cardiovascular events and atherosclerosis progression." | 2.44 | Safety considerations with niacin therapy. ( Bays, HE; Guyton, JR, 2007) |
| "Recently developed understanding of the mechanisms, efficacy, and safety of niacin, along with progress in reducing the chief side effect of flushing, should enhance the use of this valuable agent for cardiovascular prevention." | 2.44 | Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. ( Guyton, JR, 2007) |
| "The characteristic dyslipidemia of insulin resistance consists of elevated triglyceride and triglyceride-rich lipoprotein levels, low levels of high-density lipoprotein cholesterol, and increased concentrations of small, dense low-density lipoprotein cholesterol." | 2.41 | Pathophysiology and treatment of the dyslipidemia of insulin resistance. ( Capuzzi , DM; Cohn, G; Valdes, G, 2001) |
| "Hypertriglyceridemia is commonly embedded in the context of a metabolic syndrome that includes central obesity, insulin resistance, low levels of HDL cholesterol, and often hypertension." | 2.41 | A risk factor for atherosclerosis: triglyceride-rich lipoproteins. ( Kane, JP; Malloy, MJ, 2001) |
| "Patients with NIDDM are unable to increase their glucose oxidation normally in response to insulin to meet the energy demands of the body." | 2.38 | Insulin action and substrate competition. ( Ferrannini, E; Groop, LC, 1993) |
| "Niacin treatment was started from week 5 until the end of the study." | 1.56 | Niacin increases diet-induced hepatic steatosis in B6129 mice. ( Fang, H; Graff, EC; Judd, RL; Li, Z; McCafferty, KJ, 2020) |
| "Niacin was found to increase secretion of lymph HDL and miR-223 by at least 50-60% and to deplete the TGs associated with HDL compared with the nontreated IR group." | 1.48 | Intestinal lymphatic HDL miR-223 and ApoA-I are reduced during insulin resistance and restored with niacin. ( Borthwick, F; Haase, T; Jacome, M; Kontush, A; Mangat, R; Nelson, R; Proctor, SD; Vine, DF, 2018) |
| " Our aim was to find a rational NiAc dosing regimen that preserves FFA lowering, sufficient to reverse nonadipose tissue lipid accumulation and improve metabolic control, in obese Zucker rats." | 1.46 | Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S]. ( Baccega, T; Gabrielsson, J; Kroon, T; Oakes, ND; Olsén, A, 2017) |
| " FFA lowering was assessed in male Sprague Dawley (lean) and obese Zucker rats (obese) in response to a 5 h NiAc infusion, in either NiAc-naïve animals or after 5 days of continuous (24 h/day) or intermittent (12 h/day) NiAc dosing (via implantable, programmable minipump)." | 1.42 | Dosing profile profoundly influences nicotinic acid's ability to improve metabolic control in rats. ( Gabrielsson, J; Kjellstedt, A; Kroon, T; Oakes, ND; Thalén, P, 2015) |
| " At the same dosage (2 g/kg), in comparison with nicotinamide, nicotinic acid was weaker in raising plasma N(1)-methylnicotinamide levels (0." | 1.39 | Excessive nicotinic acid increases methyl consumption and hydrogen peroxide generation in rats. ( Cao, Y; Li, D; Li, SZ; Luo, N; Ma, Q; Shi, Q; Zhou, SS, 2013) |
| "Niacin has recently been shown to increase serum total concentrations of the adipocyte-derived protein adiponectin." | 1.35 | Increased total and high-molecular weight adiponectin after extended-release niacin. ( Brunson, BL; Grandjean, PW; Judd, RL; Plaisance, EP, 2008) |
| " In summary, CVT-3619 is an orally bioavailable A1 agonist that lowers circulating FFA and TG levels by inhibiting lipolysis." | 1.34 | Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. ( Belardinelli, L; Dhalla, AK; Santikul, M; Shryock, JC; Smith, M; Wong, MY, 2007) |
| "Insulin resistance is associated with increased circulating lipids and skeletal muscle lipid content." | 1.32 | Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. ( Campbell, LV; Chisholm, DJ; Ellis, BA; Gan, SK; Kelly, JJ; Kriketos, AD; O'Sullivan, A; Poynten, AM, 2003) |
| " Both PIA and PGE1 (which downregulate Gi) decreased the maximal responsiveness of the cells to insulin by approximately 30% and caused a rightward shift in the dose-response curve." | 1.30 | Insulin resistance in adipocytes after downregulation of Gi subtypes. ( Belt, SE; Green, A; Walters, DJ, 1997) |
| "Insulin resistance was induced by a 20-d continuous intravenous infusion of nicotinic acid (NA)." | 1.28 | Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons. ( Kahn, SE; Koerker, DJ; McCulloch, DK; Palmer, JP; Schwartz, MW, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.64) | 18.7374 |
| 1990's | 7 (11.48) | 18.2507 |
| 2000's | 29 (47.54) | 29.6817 |
| 2010's | 23 (37.70) | 24.3611 |
| 2020's | 1 (1.64) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, H | 1 |
| Li, Z | 1 |
| Graff, EC | 1 |
| McCafferty, KJ | 1 |
| Judd, RL | 3 |
| Mangat, R | 1 |
| Borthwick, F | 1 |
| Haase, T | 1 |
| Jacome, M | 1 |
| Nelson, R | 1 |
| Kontush, A | 1 |
| Vine, DF | 1 |
| Proctor, SD | 1 |
| Fangmann, D | 1 |
| Theismann, EM | 1 |
| Türk, K | 1 |
| Schulte, DM | 1 |
| Relling, I | 1 |
| Hartmann, K | 1 |
| Keppler, JK | 1 |
| Knipp, JR | 1 |
| Rehman, A | 1 |
| Heinsen, FA | 1 |
| Franke, A | 1 |
| Lenk, L | 1 |
| Freitag-Wolf, S | 1 |
| Appel, E | 1 |
| Gorb, S | 1 |
| Brenner, C | 1 |
| Seegert, D | 1 |
| Waetzig, GH | 1 |
| Rosenstiel, P | 1 |
| Schreiber, S | 1 |
| Schwarz, K | 1 |
| Laudes, M | 1 |
| Montastier, E | 1 |
| Beuzelin, D | 1 |
| Martins, F | 1 |
| Mir, L | 1 |
| Marqués, MA | 1 |
| Thalamas, C | 1 |
| Iacovoni, J | 1 |
| Langin, D | 1 |
| Viguerie, N | 1 |
| Li, D | 4 |
| Tian, YJ | 1 |
| Guo, J | 1 |
| Sun, WP | 2 |
| Lun, YZ | 2 |
| Guo, M | 2 |
| Luo, N | 3 |
| Cao, Y | 2 |
| Cao, JM | 1 |
| Gong, XJ | 1 |
| Zhou, SS | 4 |
| Rizvi, AA | 1 |
| Nikolic, D | 1 |
| Sallam, HS | 1 |
| Montalto, G | 1 |
| Rizzo, M | 1 |
| Abate, N | 1 |
| Heemskerk, MM | 1 |
| van den Berg, SA | 1 |
| Pronk, AC | 1 |
| van Klinken, JB | 1 |
| Boon, MR | 1 |
| Havekes, LM | 1 |
| Rensen, PC | 1 |
| van Dijk, KW | 1 |
| van Harmelen, V | 1 |
| Kopp, C | 1 |
| Hosseini, A | 1 |
| Singh, SP | 1 |
| Regenhard, P | 1 |
| Khalilvandi-Behroozyar, H | 1 |
| Sauerwein, H | 1 |
| Mielenz, M | 1 |
| Hu, M | 1 |
| Yang, YL | 1 |
| Masuda, D | 1 |
| Yamashita, S | 1 |
| Tomlinson, B | 1 |
| Kroon, T | 3 |
| Kjellstedt, A | 1 |
| Thalén, P | 1 |
| Gabrielsson, J | 3 |
| Oakes, ND | 3 |
| Le Bloc'h, J | 2 |
| Leray, V | 2 |
| Nazih, H | 1 |
| Gauthier, O | 1 |
| Serisier, S | 1 |
| Magot, T | 2 |
| Krempf, M | 2 |
| Nguyen, P | 2 |
| Ouguerram, K | 2 |
| Xiao, WY | 1 |
| Ning, N | 1 |
| Tan, MH | 1 |
| Jiang, XS | 1 |
| Zhou, L | 1 |
| Liu, L | 1 |
| Yi, D | 1 |
| Wei, P | 1 |
| Russo, L | 1 |
| Ghadieh, HE | 1 |
| Ghanem, SS | 1 |
| Al-Share, QY | 1 |
| Smiley, ZN | 1 |
| Gatto-Weis, C | 1 |
| Esakov, EL | 1 |
| McInerney, MF | 1 |
| Heinrich, G | 1 |
| Tong, X | 1 |
| Yin, L | 1 |
| Najjar, SM | 2 |
| Baccega, T | 1 |
| Olsén, A | 1 |
| Andersson, R | 1 |
| Almquist, J | 1 |
| Jirstrand, M | 1 |
| Evans, ND | 1 |
| Chappel, MJ | 1 |
| Preuss, HG | 1 |
| Echard, B | 1 |
| Perricone, NV | 1 |
| Bagchi, D | 1 |
| Yasmin, T | 1 |
| Stohs, SJ | 1 |
| Kaushik, SV | 1 |
| Plaisance, EP | 3 |
| Kim, T | 1 |
| Huang, EY | 1 |
| Mahurin, AJ | 1 |
| Grandjean, PW | 2 |
| Mathews, ST | 1 |
| Fabbrini, E | 1 |
| Mohammed, BS | 1 |
| Korenblat, KM | 1 |
| Magkos, F | 1 |
| McCrea, J | 1 |
| Patterson, BW | 1 |
| Klein, S | 1 |
| Chetiveaux, M | 1 |
| Freuchet, B | 1 |
| Zhou, YM | 2 |
| Liu, QG | 1 |
| Bian, FN | 1 |
| Zhao, ZG | 1 |
| Oh, YT | 1 |
| Oh, KS | 1 |
| Choi, YM | 1 |
| Jokiaho, A | 1 |
| Donovan, C | 1 |
| Choi, S | 1 |
| Kang, I | 2 |
| Youn, JH | 2 |
| Kim, SW | 1 |
| Hartman, R | 1 |
| Defelice, T | 1 |
| Tzu, J | 1 |
| Meehan, S | 1 |
| Sanchez, M | 1 |
| Ma, Q | 1 |
| Li, SZ | 1 |
| Shi, Q | 1 |
| Wanders, D | 1 |
| Tomono, S | 1 |
| Ohyama, Y | 1 |
| Uchiyama, T | 1 |
| Freeth, A | 1 |
| Udupi, V | 1 |
| Basile, R | 1 |
| Green, A | 2 |
| Poynten, AM | 1 |
| Gan, SK | 1 |
| Kriketos, AD | 1 |
| O'Sullivan, A | 1 |
| Kelly, JJ | 2 |
| Ellis, BA | 1 |
| Chisholm, DJ | 1 |
| Campbell, LV | 2 |
| Karpe, F | 1 |
| Frayn, KN | 1 |
| Gerber, MT | 1 |
| Mondy, KE | 1 |
| Yarasheski, KE | 1 |
| Drechsler, H | 1 |
| Claxton, S | 1 |
| Stoneman, J | 1 |
| DeMarco, D | 1 |
| Powderly, WG | 1 |
| Tebas, P | 1 |
| Dai, T | 1 |
| Abou-Rjaily, GA | 1 |
| Al-Share', QY | 1 |
| Yang, Y | 1 |
| Fernström, MA | 1 |
| Deangelis, AM | 1 |
| Lee, AD | 1 |
| Sweetman, L | 1 |
| Amato, A | 1 |
| Pasquali, M | 1 |
| Lopaschuk, GD | 1 |
| Erickson, SK | 1 |
| Asano, M | 1 |
| Yamada, N | 1 |
| Rassman, J | 1 |
| Gupta, S | 1 |
| Reasner, CA | 2 |
| Rasouli, N | 1 |
| Hale, T | 1 |
| Kahn, SE | 4 |
| Spencer, HJ | 1 |
| Elbein, SC | 1 |
| Chang, AM | 1 |
| Smith, MJ | 1 |
| Galecki, AT | 1 |
| Bloem, CJ | 1 |
| Halter, JB | 1 |
| Offermanns, S | 1 |
| Ginsberg, HN | 1 |
| Dhalla, AK | 1 |
| Santikul, M | 1 |
| Smith, M | 1 |
| Wong, MY | 1 |
| Shryock, JC | 1 |
| Belardinelli, L | 1 |
| Guyton, JR | 2 |
| Bays, HE | 1 |
| Pires, JA | 1 |
| Pescara, JB | 1 |
| Grummer, RR | 1 |
| Westphal, S | 1 |
| Luley, C | 1 |
| Novelli, M | 1 |
| Pocai, A | 1 |
| Chiellini, C | 1 |
| Maffei, M | 1 |
| Masiello, P | 1 |
| Brunson, BL | 1 |
| Groop, LC | 1 |
| Ferrannini, E | 1 |
| Saloranta, C | 1 |
| Groop, L | 1 |
| Alvarsson, M | 1 |
| Grill, V | 1 |
| Walters, DJ | 1 |
| Belt, SE | 1 |
| Vega, GL | 1 |
| Grundy, SM | 1 |
| Clore, JN | 1 |
| Harris, PA | 1 |
| Li, J | 1 |
| Azzam, A | 1 |
| Gill, R | 1 |
| Zuelzer, W | 1 |
| Rizzo, WB | 1 |
| Blackard, WG | 1 |
| Matsui, J | 1 |
| Nakamura, J | 1 |
| Ogawa, Y | 1 |
| Nakamura, T | 1 |
| Suda, T | 1 |
| Lawson, JA | 1 |
| Storlien, LH | 1 |
| Jenkins, AB | 1 |
| Whitworth, JA | 1 |
| O'Sullivan, AJ | 1 |
| Coughlan, BJ | 1 |
| Sorrentino, MJ | 1 |
| Cohn, G | 1 |
| Valdes, G | 1 |
| Capuzzi , DM | 1 |
| Malloy, MJ | 1 |
| Kane, JP | 1 |
| McCulloch, DK | 2 |
| Schwartz, MW | 2 |
| Palmer, JP | 2 |
| Porte, D | 2 |
| Koerker, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects[NCT01083329] | Phase 2 | 24 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients[NCT03973203] | 15 participants (Actual) | Interventional | 2014-06-01 | Completed | |||
| NiaMIT (NiaMIT_0001) Continuation for Early-stage Mitochondrial Myopathy Patients to Investigate the Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance[NCT04538521] | 3 participants (Actual) | Interventional | 2019-02-11 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for niacin and Insulin Resistance
| Article | Year |
|---|---|
Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents.
Topics: Adipokines; Adipose Tissue; Animals; Anti-Obesity Agents; Azetidines; Ezetimibe; Fibric Acids; Gluco | 2014 |
Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Acids, None | 2017 |
Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug.
Topics: Animals; Fatty Acids, Nonesterified; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene E | 2011 |
Acanthosis nigricans in the setting of niacin therapy.
Topics: Acanthosis Nigricans; Cardiovascular Diseases; Diagnosis, Differential; Dyslipidemias; Epidermal Gro | 2011 |
Lipid-lowering drugs and circulating adiponectin.
Topics: Adiponectin; Animals; Fatty Acids, Omega-3; Fibric Acids; Gene Expression; Humans; Hydroxymethylglut | 2012 |
[Insulin resistance induced by drugs, inflammation and stress].
Topics: Adrenergic beta-Antagonists; Benzothiadiazines; Contraceptives, Oral, Hormonal; Cyclosporins; Diabet | 2002 |
The nicotinic acid receptor--a new mechanism for an old drug.
Topics: Adipose Tissue; Animals; Cardiovascular Diseases; Fatty Acids, Nonesterified; Humans; Hypolipidemic | 2004 |
[Dyslipidemia management in patients with impaired glucose tolerance].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Clofibric Acid; Eicosapen | 2005 |
The metabolic syndrome: modify root causes, treat risk factors.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Education, Medical, Continuing; Humans; Hydroxymethylgl | 2005 |
Commentary: A new approach to atherogenic dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Hyperlipidemias; Hypolipidemic | 2005 |
What is the most effective strategy for managing diabetic dyslipidaemia?
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Drug | 2005 |
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
Topics: Animals; Flushing; Glucose Intolerance; Humans; Hypolipidemic Agents; Insulin Resistance; Niacin; Re | 2006 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.
Topics: 3-Hydroxybutyric Acid; Cardiovascular Diseases; Clinical Trials as Topic; Delayed-Action Preparation | 2007 |
Insulin action and substrate competition.
Topics: Animals; Binding, Competitive; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gluconeogenesi | 1993 |
Interactions between glucose and FFA metabolism in man.
Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Human | 1996 |
Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.
Topics: Apolipoproteins B; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans; Hydroxymethylglutaryl-C | 1998 |
[Insulin resistance induced by drugs or agents].
Topics: Animals; Antihypertensive Agents; Benzothiadiazines; Chromans; Contraceptives, Oral; Diuretics; Gluc | 2000 |
Does hypertriglyceridemia increase risk for CAD? Growing evidence suggests it plays a role.
Topics: Coronary Disease; Diabetes Complications; Evidence-Based Medicine; Humans; Hypertriglyceridemia; Hyp | 2000 |
Pathophysiology and treatment of the dyslipidemia of insulin resistance.
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2001 |
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
Topics: Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxym | 2001 |
Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction?
Topics: Amyloid; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Insulin; Insulin Resistance; Insulinoma; | 1989 |
12 trials available for niacin and Insulin Resistance
| Article | Year |
|---|---|
Niacin induces miR-502-3p expression which impairs insulin sensitivity in human adipocytes.
Topics: Adipocytes; Adipose Tissue; Adult; Cells, Cultured; Double-Blind Method; Humans; Insulin Resistance; | 2019 |
Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia.
Topics: Adiponectin; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; China; Dyslipidemias; Female | 2015 |
Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Essential Hypertension; F | 2016 |
Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome.
Topics: Adult; Aged; alpha-2-HS-Glycoprotein; Blood Proteins; C-Reactive Protein; Cholesterol, HDL; Delayed- | 2009 |
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.
Topics: Adult; Apolipoproteins B; Blood Glucose; Body Composition; Double-Blind Method; Fatty Acids, Noneste | 2010 |
Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Cholesterol; Delayed-Action Preparations; Glucose Tolerance T | 2004 |
Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic beta-cell function in nondiabetic individuals.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test | 2005 |
Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance.
Topics: Adult; Aged; Aged, 80 and over; Aging; Blood Glucose; Cholesterol; Cross-Over Studies; Double-Blind | 2006 |
Reduction of plasma NEFA concentration by nicotinic acid enhances the response to insulin in feed-restricted Holstein cows.
Topics: Abomasum; Animals; Blood Chemical Analysis; Blood Glucose; Caloric Restriction; Cattle; Fatty Acids, | 2007 |
Preferential increase in high-molecular weight adiponectin after niacin.
Topics: Adiponectin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Fatty Acids, Nonesteri | 2008 |
Changes in phosphatidylcholine fatty acid composition are associated with altered skeletal muscle insulin responsiveness in normal man.
Topics: Adult; Blood Glucose; Carbohydrate Metabolism; Cell Membrane; Fatty Acids; Female; Glucose Clamp Tec | 2000 |
Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects.
Topics: Adult; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Dou | 2000 |
27 other studies available for niacin and Insulin Resistance
| Article | Year |
|---|---|
Niacin increases diet-induced hepatic steatosis in B6129 mice.
Topics: Animals; Diet, High-Fat; Hypolipidemic Agents; Insulin Resistance; Lipid Metabolism; Lipoproteins, V | 2020 |
Intestinal lymphatic HDL miR-223 and ApoA-I are reduced during insulin resistance and restored with niacin.
Topics: Animals; Apolipoprotein A-I; Gene Expression Regulation; Insulin Resistance; Intestinal Mucosa; Lipo | 2018 |
Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans.
Topics: Adult; Case-Control Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Compoundin | 2018 |
Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats.
Topics: Animals; Betaine; Choline; CpG Islands; Dietary Supplements; DNA; DNA Damage; DNA Methylation; Epige | 2013 |
Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B.
Topics: Adaptation, Physiological; Adipocytes; Adrenergic Agents; Animals; Cells, Cultured; Cyclic Nucleotid | 2014 |
Nicotinic acid increases adiponectin secretion from differentiated bovine preadipocytes through G-protein coupled receptor signaling.
Topics: Adipocytes; Adiponectin; AMP-Activated Protein Kinases; Animals; Cattle; Cell Differentiation; Insul | 2014 |
Dosing profile profoundly influences nicotinic acid's ability to improve metabolic control in rats.
Topics: Adipose Tissue; Animals; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Glucose; Insu | 2015 |
Nicotinic Acid Accelerates HDL Cholesteryl Ester Turnover in Obese Insulin-Resistant Dogs.
Topics: Animals; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Dogs; Hypolipide | 2015 |
Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis.
Topics: Adipocytes; Adipose Tissue, White; Animals; Carcinoembryonic Antigen; Cells, Cultured; Diet, High-Fa | 2016 |
Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S].
Topics: Animals; Blood Glucose; Fasting; Fatty Acids; Glucose; Glucose Tolerance Test; Humans; Hypertriglyce | 2017 |
Comparing metabolic effects of six different commercial trivalent chromium compounds.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Chromium; DNA Fragmentation; Insulin Resistance | 2008 |
Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs.
Topics: Animals; Apolipoprotein B-100; Diacylglycerol O-Acyltransferase; Dogs; Insulin Resistance; Kinetics; | 2010 |
Chronic niacin overload may be involved in the increased prevalence of obesity in US children.
Topics: Adolescent; Adult; Appetite; Biomarkers; Blood Glucose; Child; Child, Preschool; Feeding Behavior; G | 2010 |
Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue.
Topics: Adipose Tissue; Animals; Blotting, Western; Catecholamines; Corticosterone; Fatty Acids, Nonesterifi | 2011 |
Dietary methyl-consuming compounds and metabolic syndrome.
Topics: Animals; Arsenicals; Catecholamines; Diet; Folic Acid; Homocysteine; Humans; Hypolipidemic Agents; I | 2011 |
Excessive nicotinic acid increases methyl consumption and hydrogen peroxide generation in rats.
Topics: Animals; Dose-Response Relationship, Drug; Glucose; Glucose Tolerance Test; Glycogen; Hydrogen Perox | 2013 |
Prolonged treatment with prostaglandin E1 increases the rate of lipolysis in rat adipocytes.
Topics: Adipocytes; Alprostadil; Animals; Dose-Response Relationship, Drug; Down-Regulation; Fatty Acids; GT | 2003 |
Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content.
Topics: Adult; Calorimetry, Indirect; Dietary Carbohydrates; Dietary Fats; Fasting; Fatty Acids; Fatty Acids | 2003 |
Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice.
Topics: 3-Hydroxybutyric Acid; Animals; Antigens, CD; Antigens, Differentiation; Biotin; Carcinoembryonic An | 2004 |
Niacin in the metabolic syndrome: more risk than benefit?
Topics: Blood Glucose; Humans; Insulin Resistance; Metabolic Syndrome; Niacin; Risk Assessment | 2006 |
Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adipocytes; Animals; Blood Pressure; Cell Separation; Dos | 2007 |
Free fatty acids as mediators of adaptive compensatory responses to insulin resistance in dexamethasone-treated rats.
Topics: Adaptation, Physiological; Adipose Tissue, White; Animals; Blood Glucose; Dexamethasone; Eating; Ene | 2008 |
Increased total and high-molecular weight adiponectin after extended-release niacin.
Topics: Adiponectin; Adult; Body Composition; Body Weight; Cardiovascular Diseases; Delayed-Action Preparati | 2008 |
Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders.
Topics: Adult; Blood Glucose; Fatty Acids, Nonesterified; Female; Glucagon; Humans; Insulin; Insulin Antagon | 1996 |
Insulin resistance in adipocytes after downregulation of Gi subtypes.
Topics: Adipocytes; Alprostadil; Animals; Dose-Response Relationship, Drug; GTP-Binding Proteins; Hydrogen P | 1997 |
Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hyperglycemia; Insulin; Insulin Resistance; | 1992 |
Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons.
Topics: Animals; Arginine; Diabetes Mellitus, Type 1; Fasting; Glucose; Insulin; Insulin Resistance; Islets | 1991 |